Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)

INTRODUCTION: Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), often leading to an impaired quality of life in affected patients. Current treatment modalities include antitumour necrosis factor (anti-TNF) monoclonal antibodies (mABs) including infliximab, adalimumab and golimum...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheridan, Juliette, Coe, Carol Ann, Doran, Peter, Egan, Laurence, Cullen, Garret, Kevans, David, Leyden, Jan, Galligan, Marie, O’Toole, Aoibhlinn, McCarthy, Jane, Doherty, Glen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783109/
https://www.ncbi.nlm.nih.gov/pubmed/29379609
http://dx.doi.org/10.1136/bmjgast-2017-000174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783109/
https://www.ncbi.nlm.nih.gov/pubmed/29379609
http://dx.doi.org/10.1136/bmjgast-2017-000174

Ejemplares similares